Carvedilol attenuates inflammatory-mediated cardiotoxicity in daunorubicin-induced rats

Pharmaceuticals

Volumn 4, Issue 3, 2011, Pages 551-566

  Sari, Flori R ^a,b   Arozal, Wawaimuli ^a,c   Watanabe, Kenichi ^a   Harima, Meilei ^a   Veeravedu, Punniyakoti T ^a   Thandavarayan, Rajarajan A ^a   Suzuki, Kenji ^d   Arumugam, Somasundaram ^a   Soetikno, Vivian ^a   Kodama, Makoto ^d  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b State Islamic University   (Indonesia)

^c UNIVERSITY OF INDONESIA   (Indonesia)

^d NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Carvedilol; Daunorubicin; Fibrosis; Inflammation

Indexed keywords

CARLOC; CARVEDILOL; CYCLOOXYGENASE 2; DAUNORUBICIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOTOXICITY; CELL DENSITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; GENE EXPRESSION; HEART FUNCTION; HEART INJURY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HISTOPATHOLOGY; INFLAMMATION; MALE; MAST CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; SURVIVAL RATE; TREATMENT DURATION;

EID: 79955586122     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph4030551     Document Type: Article

References (45)

1. Rahman, A.M.; Yusuf, S.W.; Ewer, M.S. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int. J. Nanomed. 2007, 2, 567-583.
2. Von Hoff, D.D.; Layard, M.W.; Basa, P.; Davis, H.L.; Von Hoff, A.L.; Rozencweig, M.; Muggia, F.M. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 1979, 91, 710-717.
3. Gaudin, P.B.; Hruban, R.H.; Beschorner, W.E.; Kasper, E.K.; Olson, J.L.; Baughman, K.L.; Hutchins, G.M. Myocarditis associated with doxorubicin cardiotoxicity. Am. J. Clin. Pathol. 1993, 100, 158-163.
4. Danesi, R.; Foqli, S.; Gennari, A.; Conte, P.; Del Tacca, M. Pharmacokinetic-pharmacodynamic relationships of the anthracyline anticancer drugs. Clin. Pharmacokinet. 2002, 41, 431-444.
5. Mercuro, G.; Cadeddu, C.; Piras, A.; Dessì, M.; Madeddu, C.; Deidda, M.; Serpe, R.; Massa, E.; Mantovani, G.; Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 2007, 12, 1124-1133.
6. Fujihira, S.; Yamamoto, T.; Matsumoto, M.; Yoshizawa, K.; Oishi, Y.; Fujii, T.; Noguchi, H.; Mori H. The high incidence of atrial thrombosis in mice given doxorubicin. Toxicol. Pathol. 1993, 21, 362-368.
7. Abou El Hassan, M.A.; Verheul, H.M.; Jorna, A.S.; Schalkwijk, C.; van Bezu, J.; van der Vijgh, W.J.; Bast, A. The new cardioprotector Monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro. Br. J. Cancer. 2003, 89, 357-362.
8. Hou, G.; Dick, R.; Abrams, G.D.; Brewer, G.J. Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice. J. Lab. Clin. Med. 2005, 146, 299-303.
9. Riad, A.; Bien, S.; Westermann, D.; Becher, P.M.; Loya, K.; Landmesser, U.; Kroemer, H.K.; Schultheiss, H.P.; Tschöpe, C. Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer. Res. 2009, 69, 695-699.
10. Soga, M.; Kamal, F.A.; Watanabe, K.; Ma, M.; Palaniyandi, S.; Prakash, P.; Veeraveedu, P.; Mito, S.; Kunisaki, M.; Tachikawa, H.; Kodama, M.; Aizawa, Y. Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. Int. J. Cardiol. 2006, 110, 378-385.
11. Umemura, M.; Kawabe, T.; Shudo, K.; Kidoya, H.; Fukui, M.; Asano, M.; Iwakura, Y.; Matsuzaki, G.; Imamura, R.; Suda, T. Involvement of IL-17 in Fas ligand-induced inflammation. Int. Immunol. 2004, 8, 1099-1108.
12. Feuerstein, G.Z.; Ruffolo, R.R. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur. Heart. J. 1996, 17, Suppl B: 24-29.
13. Alfieri, A.B.; Briceno, L.; Fragasso, G.; Spoladore, R.; Palloshi, A.; Bassanelli, G.; Montano, C.; Arioli, F.; Cuko, A.; Ruotolo, G.; Margonato, A. Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure. J. Cardiovasc. Pharmacol. 2008, 52, 49-54.
14. Kim, Y.S.; Ahn, Y.; Hong, M.H.; Joo, S.Y.; Jeong, M.H.; Kim, K.H.; Sohn, I.S.; Park, H.W.; Hong, Y.J.; Kim, J.H.; Kim, W.; Cho, J.G.; Park, J.C.; Kang, J.C. Carvedilol Inhibits Expressions of Vascular Cell Adhesion Molecule-1, Intercellular Adhesion Molecule-1, Monocyte Chemoattractant-1, and Interleukin-8 via NF-κB Inhibition in Human Endothelial Cells. Korean Circulation J. 2005, 35, 576-582.
15. Matsui, H.; Morishima, I.; Numaguchi, Y.; Toki, Y.; Okumura, K.; Hayakawa, T. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci. 1999, 65, 1265-1274.
16. Kalay, N.; Basar, E.; Ozdogru, I.; Er, O.; Cetinkaya, Y.; Dogan, A.; Inanc, T.; Oguzhan, A.; Eryol, N.K.; Topsakal, R.; Ergin, A. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J. Am. Coll. Cardiol. 2006, 48, 2258-2262.
17. Oliveira, P.J.; Bjork, J.A.; Santos, M.S.; Leino, R.L.; Froberg, M.K.; Moreno, A.J.; Wallace, K.B. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol. Appl. Pharmacol. 2004, 200, 159-168.
18. Arozal, W.; Watanabe, K.; Veeraveedu, P.T.; Ma, M.; Thandavarayan, R.A.; Sukumaran, V.; Suzuki, K.; Kodama, M.; Aizawa Y. Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicology 2010, 274, 18-26.
19. Dziegel, P; Jethon, Z.; Suder, E.; Sopel, M.; Rabczynski, L.; Surowiak, P.; Zabel, M. Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat. Exp. Toxicol. Pathol. 2002, 53, 433-439.
20. Watanabe, K.; Ohta, Y.; Nakazawa, M.; Higuchi, H.; Hasegawa, G.; Naito, M.; Fuse, K.; Ito, M.; Hirono, S.; Tanabe, N.; Hanawa, H.; Kato, K.; Kodama, M.; Aizawa, Y. Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. Br. J. Pharmacol. 2000, 130, 1489-1495.
21. Yilmaz, S.; Atessahin, A.; Sahna, E.; Karaha, I.; Ozer, S. Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity. Toxicology 2006, 218, 164-171.
22. Ibrahim, M.A.; Ashour, O.M.; Ibrahim, Y.F.; El-Bitar, H.I.; Gomaa, W.; Abdel-Rahim, S.R. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol. Res. 2009, 60, 378-381.
23. Gurusamy, N.; Watanabe, K.; Ma, M.; Zhang, S.; Muslin, A.J.; Kodama, M.; Aizawa, Y.; Dominant negative 14-3-3 promotes cardiomyocyte apoptosis in early stage of type I diabetes mellitus through activation of JNK. Biochem. Biophys. Res. Commun. 2004, 320, 773-780.
24. Yndestad, A.; Ueland, T.; Øie, E.; Florholmen, G.; Halvorsen, B.; Attramadal, H.; Simonsen, S.; Frøland, S.S.; Gullestad, L.; Christensen, G.; Damås, J.K.; Aukrust, P. Elevated levels of activin A in heart failure: potential role in myocardial remodeling. Circulation 2004, 109, 1379-1385.
25. Billingham, M.E.; Mason, J.W.; Bristow, M.R.; Daniels, J.R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer. Treat. Rep. 1978, 62, 865-872.
26. Schwartz, R.G.; McKenzie, W.B.; Alexander, J.; Sager, P.; D'Souza, A.; Manatunga, A.; Schwartz, P.E.; Berger, H.J.; Setaro, J.; Surkin, L., et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am. J. Med. 1987, 82, 1109-1118.
27. Adamcová, M.; Potáčová, A.; Popelová, O.; Stěrba, M.; Mazurová, Y.; Aupperle, H.; Geršl, V. Cardiac remodeling and MMPs on the model of chronic daunorubicin-induced cardiomyopathy in rabbits. Physiol. Res. 2010, 59, 831-836.
28. Bien, S.; Riad, A.; Ritter, C.A.; Gratz, M.; Olshausen, F.; Westermann, D.; Grube, M.; Krieg, T.; Ciecholewski, S.; Felix, S.B.; Staudt, A.; Schultheiss, H.P.; Ewert, R.; Völker, U.; Tschöpe, C.; Kroemer, H.K. The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res. 2007, 67, 10428-10435.
29. Mortensen, S.A.; Olsen, H.S.; Baandrup U. Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. Br. Heart. J. 1986, 55, 274-282.
30. Mills, P.J.; Ancoli-Israel, S.; Parker, B.; Natarajan, L.; Hong, S.; Jain, S.; Sadler, G.R.; von Känel, R. Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer. Brain. Behav. Immun. 2008, 22, 98-104.
31. Cadeddu, C.; Piras, A.; Mantovani, G.; Deidda, M.; Dessì, M.; Madeddu, C.; Massa, E.; Mercuro, G. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am. Heart. J. 2010, 160, 487.e1-487.e7.
32. Zhu, J.; Zhang, J.; Xiang, D.; Zhang, Z.; Zhang, L.; Wu, M.; Zhu, S.; Zhang, R.; Han, W. Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity. Eur. J. Pharmacol. 2010, 643, 247-253.
33. Miyata, S.; Takemura, G.; Kosai, K.; Takahashi, T.; Esaki, M.; Li, L.; Kanamori, H.; Maruyama, R.; Goto, K.; Tsujimoto, A.; Takeyama, T.; Kawaguchi, T.; Ohno, T.; Nishigaki, K.; Fujiwara, T.; Fujiwara, H.; Minatoguchi, S. Anti-Fas gene therapy prevents doxorubicin-induced acute cardiotoxicity through mechanisms independent of apoptosis. Am. J. Pathol. 2010, 176, 687-698.
34. Zheng, Y.; Ouaaz, F.; Bruzzo, P.; Singh, V.; Gerondakis, S.; Beg, A.A. NF-kappa B RelA (p65) is essential for TNF-alpha-induced fas expression but dispensable for both TCR-induced expression and activation-induced cell death. J. Immunol. 2001, 166, 4949-4957.
35. Cinquegrana, G.; D'Aniello, L.; Landi, M.; Spinelli, L.; Grande, G.; De Prisco, F.; Petretta, M. Effects of different degrees of sympathetic antagonism on cytokine network in patients with ischemic dilated cardiomyopathy. J. Card. Fail. 2005, 11, 213-219.
36. Molet, S.; Gosset, P.; Vanhee, D.; Tillie-Leblond, I.; Wallaert, B.; Capron, M.; Tonnel, A.B. Modulation of cell adhesion molecules on human endothelial cells by eosinophil-derived mediators. J. Leukoc. Biol. 1998, 63, 351-358.
37. Lin, P.Y.; Shen, H.C.; Chen, C.J.; Wu, S.E.; Kao, H.L.; Huang, J.H.; Wang, D.L.; Chen, S.C. The inhibition in tumor necrosis factor-alpha-induced attenuation in endothelial thrombomodulin expression by carvedilol is mediated by nuclear factor-kappaB and reactive oxygen species. J. Thromb. Thrombolysis 2010, 29, 52-59.
38. Wang, S.; Kotamraju, S.; Konorev, E.; Kalivendi, S.; Joseph, J.; Kalyanaraman B. Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem. J. 2002, 367, 729-740.
39. Riganti, C.; Doublier, S.; Costamagna, C.; Aldieri, E.; Pescarmona, G.; Ghigo, D.; Bosia A. Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol. Pharmacol. 2008, 74, 476-484.
40. Lee, K.M.; Kang, B.S.; Lee, H.L.; Son, S.J.; Hwang, S.H.; Kim, D.S.; Park, J.S.; Cho, H.J. Spinal NF-kB activation induces COX-2 upregulation and contributes to inflammatory pain hypersensitivity. Eur. J. Neurosci. 2004, 19, 3375-3381.
41. Niiya, M.; Niiya, K.; Kiguchi, T.; Shibakura, M.; Asaumi, N.; Shinagawa, K.; Ishimaru, F.; Kiura, K.; Ikeda, K.; Ueoka, H.; Tanimoto, M. Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells. Cancer. Chemother. Pharmacol. 2003, 52, 391-398.
42. Niu, J.; Azfer, A.; Wang, K.; Wang, X.; Kolattukudy PE. Cardiac-targeted expression of soluble fas attenuates doxorubicin-induced cardiotoxicity in mice. J. Pharmacol. Exp. Ther. 2009, 328, 740-748.
43. Mann, D.L. Inflammatory mediators and the failing heart: past, present, and in the foreseeable future. Circ. Res. 2002, 91, 988-998.
44. Chong, E.Y.; Freestone, B.; Patel, J.; Lim, H.S.; Hughes, E.; Blann, A.D.; Lip, G.Y. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am. J. Cardiol. 2006, 97, 671-675.
45. Wouters, K.A.; Kremer, L.C.; Miller, T.L.; Herman, E.H.; Lipshultz, S.E. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol. 2005, 131, 561-578.